ArticleNature medicine2026
Global and regional burden of measles and vaccine coverage among children under 5 years, 1990-2023: a Global Burden of Disease Study.
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Measles remains a leading cause of vaccine-preventable burden among children, particularly in low-income settings. Despite decades of progress, there are indications of measles resurgence due to stagnation in vaccine coverage. Here, using the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2023, we systematically assessed measles incidence, mortality, disability-adjusted life years (DALYs) and vaccine coverage (measles-containing vaccine 1 (MCV1) and measles-containing vaccine 2 (MCV2)) among children under 5 years of age across 204 countries and territories from 1990 to 2023. Between 1990 and 2019, global measles incidence and mortality declined by approximately 80% and 90%, respectively, but rebounded sharply after 2020, with 15.6 million cases and 118,000 deaths estimated in 2023 (+40% and +12% increases, respectively, between 2019 and 2023). Sub-Saharan Africa and South Asia continue to bear the highest burden. Global MCV1 coverage rose from 67.2% in 1990 to 83.6% in 2019 but stalled and declined slightly to 81.0% by 2023; MCV2 coverage increased from 14.4% in 1990 to 68.4% in 2019 and reached 71.4% by 2023. Several regions remain well below the Immunization Agenda 2030 (IA2030) target of 90% coverage. The recent measles resurgence underscores the fragility of global immunization progress and the urgent need to restore routine vaccination, close immunity gaps and strengthen outbreak preparedness.
Identifiers
42907529What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.